Precigen receives orphan drug designation for prgn-2012 for the treatment of recurrent respiratory papillomatosis from the european commission

– designation is an important step toward bringing this potentially life-changing therapy to european patients – – eu orphan drug designation is the first regulatory designation for a gorilla adenovector based immunotherapy outside of the united states for the company – germantown, md. , jan. 16, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the european commission (ec) has granted orphan drug designation for the company's first-in-class investigational medicine prgn-2012 for the treatment of recurrent respiratory papillomatosis (rrp).
PGEN Ratings Summary
PGEN Quant Ranking